- Stocks
- Healthcare
- NASDAQ: INCY

Price (delayed)

$84.62

Market cap

$18.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$17.12B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,

The debt is down by 31% year-on-year and by 25% since the previous quarter

INCY's gross profit is up by 24% year-on-year and by 9% since the previous quarter

INCY's net income has dropped by 166% year-on-year but it is up by 12% since the previous quarter

INCY's EPS has shrunk by 165% YoY but it is up by 13% QoQ

What are the main financial stats of INCY

Market
Valuations
Earnings

Shares outstanding

219.84M

Market cap

$18.6B

Enterprise value

$17.12B

Price to earnings (P/E)

N/A

Price to book (P/B)

7.1

Price to sales (P/S)

6.92

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

6.42

Revenue

$2.67B

EBIT

-$230.04M

EBITDA

-$178.24M

Free cash flow

-$311.98M

Per share
Balance sheet
Liquidity

EPS

-$1.36

Free cash flow per share

-$1.43

Book value per share

$11.92

Revenue per share

$12.23

TBVPS

$14.83

Total assets

$3.56B

Total liabilities

$949.65M

Debt

$34.86M

Equity

$2.61B

Working capital

$1.73B

Debt to equity

0.01

Current ratio

3.74

Quick ratio

3.62

Net debt/EBITDA

8.3

Margins
Efficiency
Dividend

EBITDA margin

-6.7%

Gross margin

95.1%

Net margin

-11.1%

Operating margin

-9%

Return on assets

-9.2%

Return on equity

-12.7%

Return on invested capital

-23.1%

Return on capital employed

-7.9%

Return on sales

-8.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Incyte stock price performed over time

Intraday

0.52%

1 week

2.35%

1 month

5.97%

1 year

-16.96%

YTD

-2.71%

QTD

4.12%

How have Incyte's revenue and profit performed over time

Revenue

$2.67B

Gross profit

$2.54B

Operating income

-$240.29M

Net income

-$295.7M

Gross margin

95.1%

Net margin

-11.1%

INCY's net income has dropped by 166% year-on-year but it is up by 12% since the previous quarter

Incyte's operating income has plunged by 157% YoY but it has increased by 22% from the previous quarter

The net margin has dropped by 154% year-on-year but it is up by 18% since the previous quarter

INCY's operating margin has dropped by 146% year-on-year but it is up by 29% since the previous quarter

What is Incyte's growth rate over time

What is Incyte stock price valuation

P/E

N/A

P/B

7.1

P/S

6.92

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

6.42

INCY's EPS has shrunk by 165% YoY but it is up by 13% QoQ

The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 16.8 and 15% less than its last 4 quarters average of 8.3

INCY's equity is up by 9% since the previous quarter

INCY's P/S is 41% below its 5-year quarterly average of 11.7 and 13% below its last 4 quarters average of 7.9

Incyte's revenue has increased by 24% YoY and by 9% from the previous quarter

How efficient is Incyte business performance

The ROE has plunged by 166% YoY but it has grown by 12% from the previous quarter

INCY's return on assets has dropped by 163% year-on-year but it is up by 12% since the previous quarter

INCY's ROS has shrunk by 138% YoY but it is up by 23% QoQ

The ROIC has plunged by 137% YoY but it has increased by 22% from the previous quarter

What is INCY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INCY.

How did Incyte financials performed over time

The current ratio has contracted by 23% YoY but it has grown by 5% from the previous quarter

The company's quick ratio fell by 23% YoY but it rose by 4.9% QoQ

The debt is 99% smaller than the equity

The debt to equity has plunged by 50% from the previous quarter and by 50% YoY

The debt is down by 31% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.